Multi Institutional Phase II Trial of Single Agent Regorafenib in Refractory Advanced Biliary Cancers
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Aug 2019
Price : $35 *
At a glance
- Drugs Regorafenib (Primary)
- Indications Biliary cancer; Cholangiocarcinoma; Gallbladder cancer
- Focus Therapeutic Use
- 05 Aug 2019 Planned primary completion date changed from 1 Oct 2019 to 1 Dec 2019.
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 13 May 2019 According to a Bayer media release, data from this study will be presented in the upcoming 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2019, taking place May 31 to June 4 in Chicago, Illinois (USA).
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History